DR. DAVID MERVYN MARGULIES, M.D.
Medical Practice at Bradley Blvd, Bethesda, MD

License number
Maryland D0008454
Category
Medical Practice
Type
Gynecology
Address
Address
8231 Bradley Blvd, Bethesda, MD 20817
Phone
(301) 365-0075

Personal information

See more information about DAVID MERVYN MARGULIES at radaris.com
Name
Address
Phone
David Margulies, age 74
7805 Radnor Rd, Bethesda, MD 20817
(301) 229-1691
David M Margulies, age 89
8231 Bradley Blvd, Bethesda, MD 20817
(301) 365-0075
David O Margulies, age 113
5 Cobblestone Ct, Baltimore, MD 21215
(410) 486-0396
David H Margulies, age 74
7805 Radnor Rd, Bethesda, MD 20817
(301) 229-1691
David Margulies
Bethesda, MD
(301) 365-0075

Professional information

See more information about DAVID MERVYN MARGULIES at trustoria.com
David M Margulies Photo 1
Dr. David M Margulies, Bethesda MD - MD (Doctor of Medicine)

Dr. David M Margulies, Bethesda MD - MD (Doctor of Medicine)

Specialties:
Obstetrics & Gynecology
Address:
8231 Bradley Blvd, Bethesda 20817
(301) 365-0075 (Phone), (301) 365-0075 (Fax)
Certifications:
Obstetrics & Gynecology, 1967
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Northwestern Center Feinberg School of Medicine
Graduated: 1961
George Washington University Medical Center
Charity Hospital


David Margulies Photo 2
Potent Peptide For Stimulation Of Cytotoxic T Lymphocytes Specific For The Hiv-1 Envelope

Potent Peptide For Stimulation Of Cytotoxic T Lymphocytes Specific For The Hiv-1 Envelope

US Patent:
5976541, Nov 2, 1999
Filed:
Mar 6, 1992
Appl. No.:
7/847311
Inventors:
Jay A. Berzofsky - Bethesda MD
Mutsunori Shirai - Rockville MD
C. David Pendleton - Bethesda MD
Steven Kozlowski - Washington DC
David H. Margulies - Bethesda MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
A61K 3921, A61K 3938, A61K 3912, C12N 1500
US Classification:
4241881
Abstract:
Peptides having high activity in the eliciting of a cytotoxic T lymphocyte response to the HIV-1 envelope glycoprotein gpl60 are described. The activation of 12-15 residue peptides by proteolytic degradation to shorter peptides is shown as are general techniques for characterizing such activation processes.